Fulgent Genetics Reports First Quarter 2018 Financial Results

Genetics Investing

Fulgent Genetics (NASDAQ:FLGT) announced financial results for its first quarter ended March 31, 2018. As quoted in the press release: First quarter revenue was $4.7 million, an increase of 9% sequentially from $4.3 million in the fourth quarter of 2017, and a decrease of 12% year over year from $5.3 million in the first quarter …

Fulgent Genetics (NASDAQ:FLGT) announced financial results for its first quarter ended March 31, 2018.

As quoted in the press release:

First quarter revenue was $4.7 million, an increase of 9% sequentially from $4.3 million in the fourth quarter of 2017, and a decrease of 12% year over year from $5.3 million in the first quarter of 2017. GAAP loss for the first quarter of 2018 was $1.9 million, or $0.11 per share, and non-GAAP loss was $1.2 million, or $0.06 per share. Adjusted EBITDA loss was $1.1 million in the first quarter of 2018.

Non-GAAP loss and adjusted EBITDA are described below under “Note Regarding Non-GAAP Financial Measures” and are reconciled to the most directly comparable GAAP financial measure, GAAP income (loss), in the accompanying tables.

Click here to read the full press release.

The Conversation (0)
Ă—